Study setting and participants
hair loss, hypertrophic scars
HAIR LOSS, BLOOD CLOTTING DISORDERS
Our study was conducted in the dermato-venereology outpatient clinic of Dr. Cipto Mangunkusumo Hospital for 3 months, from October 2021 to December 2021. The authors received ethical approval from the Health Research Ethics Committee—Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo Hospital with decision number KET-219/UN2.Fl/ETIK/PPM.00′00/2020 prior to the study. Male AGA patients between the ages of 25 and 59 years old whose clinical presentation met Hamilton-Norwood criteria grades II to VI were included in the study. Cessation of anti-androgens and minoxidil treatment for at least 1 month was mandatory. The following were the criteria for exclusion:patients with hair loss other than AGApatients receiving 5-alpha reductase inhibitor therapy;patients who had received growth factor treatment (platelet-rich plasma or microneedling) for at least 6 months prior to the study; andhistory of hypertrophic scars or blood clotting disorders.Study participants were split into two treatment groups: 20 received concentrated ADSC-CM, and 17 received non-concentrated ADSC-CM on the treated scalp section. The sample size was calculated using Federer’s formula. Patients were dropped out of the study if they experienced severe side effects, withdrew, or failed to follow the appointed protocol.